Home > Oncology > ESMO 2022 > Letter from the Editor

Letter from the Editor

Dr Stefan Rauh, the Centre Hospitalier Emile Mayrisch, Esch, Luxembourg
ESMO 2022

Dear reader,

Have you ever seen a water-fall plot looking like a lake before? If you attended this year’s Presidential Session, you did, if not: check the amazing results of the NICHE-2 study in deficient DNA mismatch repair (dMMR) colorectal cancer.

Precision medicine provides a new option in intrahepatic cholangiocarcinoma: mFGFR2 carriers achieve significant benefits with a new, highly selective FGFR inhibitor.

Sip a “Bellini” while going through the same-named study: a high percentage of tumour infiltrating lymphocytes (TILs) is predictive of good neoadjuvant response with checkpoint blockade.

Sacituzumab govitecan may be the new standard for HR-positive HER2-negative advanced breast cancer refractory to hormonal treatment.

Also, there is amazing news in melanoma treatment: Just 3 neoadjuvant cycles can make the difference in recurrence-free survival, according to a study comparing purely adjuvant versus neoadjuvant/adjuvant pembrolizumab, in resectable stage III and IV melanoma patients.

…and reinfusing harvested and in-vitro expanded tumour infiltrating lymphocytes outperforms 2nd line checkpoint inhibition in metastatic melanoma patients.

And please check out Charles Swanton’s fantastic presentation of the pathogenesis from air pollution to lung cancer: a milestone event.

As always, you’ll find all of the above in detail below, and there’s a lot more to digest.

I hope you enjoy our ESMO 2022 congress report.

Yours, sincerely

Stefan Rauh



Dr Stefan Rauh is currently working as haematooncologist in the oncology department of the Centre Hospitalier Emile Mayrisch, Esch, Luxembourg. He is mainly involved in clinical work but also in research and teaching activities and is interested in public policy and international cooperation projects in oncology. He is member of the ESMO Practicing Oncologist’s Working Group since 2011 (chair 2014-2018) and the ESMO Public Policy Committee, and has been an ESMO Executive Board member in 2015-2016. He is co-author of the 2017 ESMO European Cancer Patient Coalition (ECPC) Patient Survivorship Guide and an invited expert for the ECPC.

Conflict of Interest Statement: Nothing to declare.

Posted on